USAGE OF SILVER NANOPARTICLES TO RESTORE MOXIFLOXACIN EFFICACY FOR FLUOROQUINOLONE-RESISTANT M. TUBERCULOSIS CULTURES.

Background: Fluoroquinolones are used for the complex treatment of mono-, poly-, and multi-resistant Tuberculosis (TB) and are the most efficient among resistant TB treatment drugs. Disease caused by fluoroquinolone-resistant TB strains, especially pre-extensive TB (pre-XDR) and extensive (XDR) forms are extremely hard to manage, and treatment efficacy is quite low. With the revitalization and extension of resistant TB drugs, one of the main research domains is to study resistance inhibitors aimed at restoring the efficacy of main and priority anti-TB medications.

EFFICACY AND SAFETY OF SILVER NANOCOMPOSITES ON RIFAMPICIN-RESISTANT M. TUBERCULOSIS STRAINS.

Background: Control of rifampicin-resistant tuberculosis (RR-MTB) requires novel technologies for restoring the anti-TB efficacy of priority drugs. We sought to evaluate the ability of nanotechnology application in the recovery of the anti-tuberculosis efficacy of rifampicin.

Methods: Nanocomposite- standard dose of rifampicin and 20 nm silver nanoparticles (AgNPs) suspension solution of 6 different concentrations: 0.

Hepatitis C care cascade among patients with and without tuberculosis: Nationwide observational cohort study in the country of Georgia, 2015-2020.

Background: The Eastern European country of Georgia initiated a nationwide hepatitis C virus (HCV) elimination program in 2015 to address a high burden of infection. Screening for HCV infection through antibody testing was integrated into multiple existing programs, including the National Tuberculosis Program (NTP). We sought to compare the hepatitis C care cascade among patients with and without tuberculosis (TB) diagnosis in Georgia between 2015 and 2019 and to identify factors associated with loss to follow-up (LTFU) in hepatitis C care among patients with TB.

Treatment of hepatitis C in primary health care in the country of Georgia.

Content available: Audio Recording.

The prevalence of hyperglycemia and its impact on mortality among people living with HIV in Georgia.

Background: Life expectancy and quality of life of people living with HIV have been dramatically improved after introducing antiretroviral therapy, and the prevalence of non-communicable diseases has increased. Several studies have found that hyperglycemia with or without type 2 diabetes was associated with poor outcomes in people living with HIV. The study's objective was to determine the prevalence of hyperglycemia and assess its impact on mortality.